KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $22.9 million.

  • Sarepta Therapeutics' Capital Expenditures fell 3845.37% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.5 million, marking a year-over-year increase of 1573.19%. This contributed to the annual value of $137.0 million for FY2024, which is 7995.43% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Capital Expenditures of $22.9 million as of Q3 2025, which was down 3845.37% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Capital Expenditures registered a high of $43.7 million during Q1 2025, and its lowest value of $2.2 million during Q4 2021.
  • Its 5-year average for Capital Expenditures is $20.0 million, with a median of $19.0 million in 2023.
  • Per our database at Business Quant, Sarepta Therapeutics' Capital Expenditures tumbled by 9228.94% in 2021 and then soared by 26101.54% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Capital Expenditures (Quarter) stood at $2.2 million in 2021, then soared by 261.02% to $8.0 million in 2022, then soared by 139.06% to $19.0 million in 2023, then surged by 100.02% to $38.1 million in 2024, then crashed by 39.78% to $22.9 million in 2025.
  • Its Capital Expenditures was $22.9 million in Q3 2025, compared to $31.8 million in Q2 2025 and $43.7 million in Q1 2025.